NewsAI-assisted

Lantheus Achieves Phase 3 Endpoints for TAUKLARIFY in Early Alzheimer's Disease

Lantheus presents Phase 3 data for TAUKLARIFY tau-PET agent, meeting all sensitivity and specificity endpoints across 617 scans in early Alzheimer's disease.

Vaibhavi M.
By Vaibhavi M.
Subject Matter Expert · Pharma Now
Nov 17, 20262 min read
Lantheus Achieves Phase 3 Endpoints for TAUKLARIFY in Early Alzheimer's Disease
AI-assisted reporting
Reviewed by Vaibhavi M., Subject Matter Expert · Pharma Now
80/ 100
Trust score
High confidence

Radiopharmaceutical manufacturing and QA teams should take note: Lantheus has presented pivotal Phase 3 data for TAUKLARIFY (florquinitau F 18 injection), a tau-targeted PET imaging agent, with results that strengthen the regulatory case for broader clinical deployment in early Alzheimer's disease diagnosis. The data, presented at CTAD 2026 in Boston, showed all five independent readers meeting prespecified co-primary endpoints of sensitivity and specificity across both studies.

The two pivotal studies evaluated 617 TAUKLARIFY PET scans drawn from three established prospective Alzheimer's disease cohorts. A prospectively defined clinical and radiological reference standard, informed by neuropathological evidence, classified amyloid beta PET-positive individuals with cognitive impairment as tau-positive and age-matched amyloid beta-negative cognitively normal individuals as tau-negative. Independent reader assessments were benchmarked against this framework, yielding high inter-reader agreement across both studies.

For QA directors and regulatory leads, the diagnostic consistency across two independent pivotal studies carries direct process implications. F-18 radiopharmaceuticals carry a 110-minute physical half-life, compressing the window between synthesis, QC release testing, and patient administration into a sequence that leaves little tolerance for deviation. As tau-PET imaging scales toward routine clinical use, manufacturing sites will face intensifying pressure on batch release timelines, in-process controls, and the logistics of regional distribution, all within a 21 CFR Part 211 and GMP-compliant framework.

The reference standard methodology used here is also operationally significant. By anchoring diagnostic performance to amyloid beta PET status rather than post-mortem histopathology alone, the studies enabled inclusion of early symptomatic patients, a population that had previously been difficult to characterize in pivotal imaging trials. That design choice expands the intended use population and, by extension, the projected scan volume that manufacturing networks will need to support.

Lantheus has positioned TAUKLARIFY alongside amyloid beta imaging as a complementary diagnostic tool, a pairing that, if adopted at scale, would require imaging centers and radiopharmacy networks to manage concurrent short-lived isotope workflows under tightly controlled conditions.

The measurable outcome to watch is whether the Phase 3 dataset, as presented at CTAD 2026, translates into a broadened FDA-approved indication or updated labeling that formally encompasses early symptomatic Alzheimer's disease populations.

Source: Lantheus Holdings, Inc. via GlobeNewswire, November 16, 2026. Data presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2026 meeting, Boston, Massachusetts.

Read the original release ↗
TopicsNews
Vaibhavi M.
Written by
Vaibhavi M.
Subject Matter Expert · Pharma Now

Reporting on the science, business and regulation shaping the pharmaceutical industry.

Discussion

Loading discussion…

More from Pharma News

All stories →